Merger Notification - Announcement according to § 10 Cartel Act
Amgen Inc.; Celgene Corporation
BWB/Z-4585
On 10.09.2019 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Amgen Inc. (Thousand Oaks, California, USA) intends to acquire all assets related to Otezla, a product currently owned and marketed by Celgene Corporation (Summit, New Jersey, USA). The proposed concentration concerns pharmaceutical products for the treatment of moderate-to-severe psoriasis and psoriatic arthritis.
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 08.10.2019.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 09.10.2019 .